{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_20952", "batch_size": 200, "batch_pos": 86, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "'plans to launch' and 'could respond very quickly' are neutral phrases. No high-potency language is present.", "method": "llm_batch", "batch_id": "batch_2_20832", "batch_size": 200, "batch_pos": 54, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "'began' and 'modified' are not moderate verbs from the list.", "method": "llm_batch", "batch_id": "batch_3_20640", "batch_size": 200, "batch_pos": 191, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_12308", "batch_size": 200, "batch_pos": 181, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment reports historical context of research but contains no explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_13792", "batch_size": 200, "batch_pos": 175, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "No minimiser or scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_20484", "batch_size": 200, "batch_pos": 130, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment describes research history but contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_6596", "batch_size": 200, "batch_pos": 119, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 8, "answer": "no", "rationale": "The segment describes the origin of research, not current capability or preparedness.", "method": "llm_batch", "batch_id": "batch_8_17476", "batch_size": 200, "batch_pos": 154, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 9, "answer": "no", "rationale": "The segment reports research history, not prices or metrics.", "method": "llm_batch", "batch_id": "batch_9_16844", "batch_size": 200, "batch_pos": 82, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 10, "answer": "no", "rationale": "The segment reports research history, not speculation about future relief.", "method": "llm_batch", "batch_id": "batch_10_20452", "batch_size": 200, "batch_pos": 68, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 11, "answer": "no", "rationale": "'said Raffael Nachbagauer' introduces reported speech, not a direct quotation.", "method": "llm_batch", "batch_id": "batch_11_6176", "batch_size": 200, "batch_pos": 66, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
{"Q": 12, "answer": "yes", "rationale": "No explicit framing cues remain; segment reports research history factually.", "method": "llm_batch", "batch_id": "batch_12_7696", "batch_size": 200, "batch_pos": 66, "statement_text": "Moderna's mRNA vaccine research actually began with pandemic flu, and was modified for COVID, said Raffael Nachbagauer, executive director of infectious diseases at Moderna.", "article_id": 1272}
